TLDR Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
This systematic review and meta-analysis examined the association between mineralocorticoid receptor antagonist (MRA) therapy and mortality in SARS-CoV-2 patients, involving 1,388,178 subjects, with 80,903 receiving MRA therapy. The study found no significant reduction in mortality associated with MRA therapy, with an odds ratio of 0.387 and a 95% confidence interval of 0.134–1.117 (p = 0.079). Despite MRAs' potential protective effects against tissue fibrosis and inflammation, the results did not support a beneficial impact on mortality rates in COVID-19 patients. The study emphasized the need for larger-scale randomized controlled trials to further explore this relationship.
8 citations
,
April 2021 in “Medical journal of the Islamic Republic of Iran”
Taking finasteride can partially improve oxygen levels in hospitalized male patients over 50 with COVID-19 pneumonia, but it doesn't affect other outcomes like death rate or hospital stay length.
Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.
119 citations
,
May 2020 in “Journal of The American Academy of Dermatology”
Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.
Hair loss treatments discussed include Minoxidil, Finasteride, and Spironolactone. One user shares success with Finasteride, Minoxidil, and low-dose Cyproterone Acetate, but warns against long-term use of oral anti-androgens.
A user experienced facial swelling while taking spironolactone for androgenic alopecia, despite its diuretic properties. They are unsure about increasing the dose due to this side effect.
Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.
41-year-old female experienced slow hair thinning, took finasteride for a year, then switched to spironolactone. Irregular periods occurred, seeking advice on long-term side effects and considering a third medication.
Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.
